Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014:2014:184297.
doi: 10.1155/2014/184297. Epub 2014 Mar 3.

Does Statin or ASA Affect Survival When Prostate Cancer Is Treated with External Beam Radiation Therapy?

J Caon  1 , M Paquette  2 , J Hamm  3 , T Pickles  4
Affiliations

Does Statin or ASA Affect Survival When Prostate Cancer Is Treated with External Beam Radiation Therapy?

J Caon et al. Prostate Cancer. 2014.

Abstract

Background. Prior studies evaluating the effect of statins or acetylsalicylic acid (ASA) on the survival of men receiving prostate cancer were treatment have reported conflicting results, and have not adjusted for comorbidity. Our aim is to investigate the influence of statins and ASA on prostate cancer survival, when comorbidity is adjusted for, in men treated with external beam radiation therapy (EBRT) for prostate cancer. Methods. A cohort of 3851 patients with prostate cancer treated with curative EBRT ± androgen deprivation therapy (ADT) between 2000 and 2007. Stage, treatment, medication use, and Charlson comorbidity index (CCI) scores were analyzed. Results. Median followup was 8.4 years. Mean age was 70.3 years. Neoadjuvant ADT was used in 67%. Statins were used in 23%, ASA in 24%, and both in 11%. Comorbidity scores were 0 in 65%, 1 in 25%, and ≥2 in 10% of patients. Statin and ASA use were associated with increased age and comorbidity. Although statin and ASA use were significantly associated with improved prostate cancer specific survival (PCSS) on univariate analysis, neither were on multivariate analysis. Conclusion. Neither statin nor ASA use impacted PCSS on multivariate competing risks analysis. Survival was impacted by increased comorbidity as well as statin and ASA use.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Prostate cancer specific survival between statin users and nonusers.
See this image and copyright information in PMC

References

    1. e-CPS English. e-CPS : Drug Monographs : HMG-CoA Reductase Inhibitors (CPhA Monograph) 2011, https://www.e-therapeutics.ca/cps.showMonograph.action?simpleMonographId....
    1. Hamilton RJ, Goldberg KC, Platz EA, Freedland SJ. The influence of statin medications on prostate-specific antigen levels. Journal of the National Cancer Institute. 2008;100(21):1511–1518. - PubMed
    1. Oh HY, Lee EJ, Yoon S, Chung BH, Cho KS, Hong SJ. Cholesterol level of lipid raft microdomains regulates apoptotic cell death in prostate cancer cells through EGFR-mediated Akt and ERK signal transduction. The Prostate. 2007;67(10):1061–1069. - PubMed
    1. Yang L, Egger M, Plattner R, Klocker H, Eder IE. Lovastatin causes diminished PSA secretion by inhibiting AR expression and function in LNCaP prostate cancer cells. Urology. 2011;77(6):1508.e1–1508.e7. - PubMed
    1. Yokomizo A, Shiota M, Kashiwagi E, et al. Statins reduce the androgen sensitivity and cell proliferation by decreasing the androgen receptor protein in prostate cancer cells. The Prostate. 2011;71(3):298–304. - PubMed

LinkOut - more resources